Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah M Dry

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
Oncotarget|June 11, 2016
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Murakami, Arun S Singh, Tasuku Kiyuna, et al.
Oncotarget|April 14, 2017
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Murakami, Shukuan Li, Qinghong Han, et al.
Biochemical and Biophysical Research Communications|November 6, 2018
Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcomaKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
The Journal of Pathology|November 6, 2009
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumoursSubbaya Subramanian, Venugopal Thayanithy, Robert B West, et al.
Journal of Cellular Biochemistry|November 17, 2017
Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninaseKentaro Igarashi, Shukuan Li, Qinghong Han, et al.
Surgery|October 10, 2025
Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly one half of referred patientsMark A Eckardt, Nicholas M Siena, Amy R Copeland, et al.
Oncotarget|May 4, 2018
Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse modelKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Cell Cycle (Georgetown, Tex.)|January 30, 2018
Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinicKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Cancer Letters|January 7, 2018
Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcomaKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
JAMA Network Open|December 17, 2025
Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical TrialJohn Nikitas, Joseph K Kendal, Ricky R Savjani, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Oncotarget|June 11, 2016
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Murakami, Arun S Singh, Tasuku Kiyuna, et al.
Oncotarget|April 14, 2017
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Murakami, Shukuan Li, Qinghong Han, et al.
Biochemical and Biophysical Research Communications|November 6, 2018
Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcomaKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
The Journal of Pathology|November 6, 2009
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumoursSubbaya Subramanian, Venugopal Thayanithy, Robert B West, et al.
Journal of Cellular Biochemistry|November 17, 2017
Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninaseKentaro Igarashi, Shukuan Li, Qinghong Han, et al.
Surgery|October 10, 2025
Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly one half of referred patientsMark A Eckardt, Nicholas M Siena, Amy R Copeland, et al.
Oncotarget|May 4, 2018
Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse modelKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Cell Cycle (Georgetown, Tex.)|January 30, 2018
Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinicKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Cancer Letters|January 7, 2018
Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcomaKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
JAMA Network Open|December 17, 2025
Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical TrialJohn Nikitas, Joseph K Kendal, Ricky R Savjani, et al.
Pageof 15